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Abstract
Background: In China, the incidence of Inflammatory bowel disease (IBD) has shown a significant growth trend.
Analysis of the epidemiology, clinical manifestations, diagnostic means, and treatment of IBD will further improve the
clinician's understanding of IBD, improve knowledge and further enable early diagnosis and standardized therapeutic
management. The purpose of this study was to analyze the clinical characteristics of IBD inpatients in General Hospital of
NingXia Medical University over a 12-year period to identify trends in clinical and epidemiological features, clinical
manifestations, and treatment programs.
Methods: By excluding188 patients with incomplete information or incompatible with the 2012 Guidlines cases,
we retrospectively analyzed the case records of 567 inpatients with a diagnosis of IBD admitted to the General
Hospital of NingXia Medical University between January 2002 and December 2014. The clinical epidemiological
features, clinical manifestations, diagnostic methods, and therapeutic status were analyzed.
Results: Over the study period, IBD hospitalization rates in 2002 and 2014 groups was 1.96 % and 4.05 %, increased
2.07 times. Of 567 cases of IBD, 483 (85.19 %) cases were categorized as ulcerative colitis (UC) and 84 as Crohn’s disease
(CD) (14.81 %). Total male cases were 321 (56.61 %). Mean age of cases was 49.06 ± 14.92 years for UC and 44.84 ±
14.67 years for CD. The majority of UC was located in the colon, with a moderate level of disease activity. A
combination of clinical manifestations and colonoscopy was mostly used to make a diagnosis; relatively the rate of
pathological diagnosis was low, with a small proportion of patient’s diagnosed based on radiology. Treatment with
SASP/5ASA and steroids was applied to the majority of inpatients and 47.83 % were treated with antibiotics; in
contrast, only 1.86 % cases were treated with immunosuppressive therapy.
Conclusions: An increasing trend of admissions for IBD can be observed in our study; there are some differences in
clinical features and treatment compared with Western countries, and further research into this is required.
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Background
Inflammatory bowel disease (IBD) is a general diagnostic
term that describes conditions with idiopathic, chronic,
relapsing, and remitting inflammation of the gastrointes-
tinal tract; include Ulcerative Colitis (UC) and Crohn’s
Disease (CD), which has both overlapping and distinct
clinical and pathological features. Although incidence
and prevalence of IBD are beginning to stabilize in high-
incidence areas, they continue to rise in low-incidence
areas such as southern Europe, Asia, and much of the de-
veloping world [1, 2]. Current published data on IBD in
Europe gives a prevalence of IBD as between 0.5 % and
1 % of the population. In China, the incidence has shown
a significant growth trend [3–6] since 1956, when the Pe-
king Union Medical College Hospital reported the first
cases of IBD [7]. Despite this, the pathogenesis of IBD is
incompletely understood. Genetic and environmental fac-
tors, such as altered luminal bacteria and enhanced
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intestinal permeability, play a role in the deregulation of
intestinal immunity, leading to gastrointestinal injury. The
clinical features of IBD may provide some clues to the
cause of disease. IBD not only causes growth failure and
retarded sexual development in young people, but can also
result in psychological problems. Medical treatments such
as corticosteroids or immunosuppressive drugs cause sec-
ondary health problems, and surgery may result in compli-
cations such as intestinal failure, colorectal cancer, or sepsis
[8]. Analysis of the epidemiology, clinical manifestations,
diagnostic means, and treatment of IBD will further im-
prove the clinician's understanding of IBD, improve know-
ledge and further enable early diagnosis and standardized
therapeutic management. To this end, the Chinese Medical
Association of Gastroenterology has developed a research-
based consensus opinion on the diagnosis and treatment of
IBD, published and updated in 1978, 1993, 2000, 2007, and
2012. These revisions are dependent on the analysis of clin-
ical data from Western countries due to a lack of large-
scale epidemiological, clinical studies and an inadequate
follow-up system in China. However, owing to differences
in environment, ethnicity, lifestyle, and so on, disease
characteristics will not be exactly the same. China is in
urgent need of more multi-center, well-designed clinical
research in order to develop treatment guidelines based
on local conditions.
The aim of this study was to analyze clinical characteris-
tics such as epidemiology, method of diagnosis, and treat-
ment of hospitalized patients with IBD, over a 12-year
period at the General Hospital of NingXia Medical Univer-
sity, which is the largest and has a degree of representivity
in the region. These data would be a useful observation of
the increase in IBD incidence and prevalence in China, and
provide valuable information for the proper diagnosis and
management of the disease.
Methods
In this retrospective survey we reviewed the medical re-
cords of inpatients with IBD admitted to the General Hos-
pital of NingXia Medical University between January 2002
and December 2014. These high quality records have pre-
viously been used as a database for epidemiologic research
into diagnoses, treatment, and hospitalizations. Data ob-
tained were checked according to the 2012 guidelines for
the diagnosis and treatment of IBD [9]. Moreover, we only
recorded the first hospitalization data for repeatedly hospi-
talized patients (Fig. 1). A standard comprehensive data
form was designed to collect general information, for every
patient and medical record collected from the Medical
Record Database. This information included age, gender,
year of diagnosis, clinical manifestations, complications, la-
boratory tests, treatments (e.g., 5-amino salicylic acid, pro-
biotics, corticosteroids, immunosuppressive agents etc.)
and these data were retrospectively analyzed. In addition,
we have divided the patients’ occupational physical activity
into three degrees. Mild class means they are mainly sed-
entary and do not walk much around at workplace, for ex-
ample, desk work, work including assembling of minor
parts. Serve class means they have heavy physical work,
they carry heavy burdens and carry out physically strenu-
ous work, for example, work including digging and shovel-
ing. Moderate class is the people performing the work
whose physical strength is between the mild and severe
physical activity. We simultaneously collected data on all
gastrointestinal (GI) cases from 2002 to 2014 to calculate
the proportion of IBD.
Statistical analysis was performed with SPSS software
(version 17.0). All results are expressed as mean (SD)
and percentage.
This study was approved by the General Hospital of
NingXia Medical University Ethics Committee and is in
compliance with the Helsinki Declaration. Access to the
health databases is controlled by General Hospital of
NingXia Medical University, and was approved by the ac-
cess committee following review of the application and re-
ceipt of ethics approval. All enrolled patients agreed to




A total of 567 patients, including 483 with UC (85.19 %)
and 84 with CD (14.81 %), were examined from 2002 to
2014. The number of GI inpatients admitted generally
increased over the study period and an important turn-
ing point is seen for 2008 (Table 1). The proportion of
GI patients with IBD also increased year on year, with a
highest proportion 5.16 %, admitted in 2007. As shown
in Table 1, the number (proportion) of IBD patients hos-
pitalized with UC increased from 15 (1.96 %) in 2002 to
59 (3.27 %) in 2014, and with CD from 0 in 2002 to 14
(0.78 %) in 2014. Although the proportion of IBD pa-
tients hospitalized for CD is increasing, the vast majority
of patients admitted with IBD had UC.
General characteristics
A total of 483 patients with UC were studied, with a male:
female ratio of 1.22:1. The majority of these (n = 274;
56.73 %) were living in urban areas, the remainder in rural
areas. The most common occupation type was manual
work (n = 281; 58.18 %), followed by intermediate work
(n = 107; 22.15 %) and mental work (n = 95; 19.67 %).
Age ranged from 13 to 88 years, with mean age 49.06 years
(SD: 14.92), with no difference in mean age between males
and females. According to Montreal classification for age,
the majority of patients were >40 years (72.46 %). For dis-
ease localization, pancolitis accounted for 233 (48.24 %) of
UC inpatients (33.13 % left colon, 18.63 % rectum).
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Interestingly, the majority of UC patients had moderate
luminal inflammation (n = 180; 37.27 %), followed by mild
(n = 154; 31.88 %) and severe (n = 149; 30.85 %). Their
situation at discharge was assessed based on Mayo Score
which include four aspects: defecation frequency, hemato-
chezia, endoscopic and physicians overall assessment, and
revealed that after treatment the majority scored ≦2 or
single event ≦1. This suggests that on discharge 179
(37.06 %) were in clinical remission, 157 (32.50 %) had
mild disease activity and 136 (28.16 %) had moderate dis-
ease activity (Table 2).
Of the 84 patients with CD, 55 (65.48 %) were male and
29 (34.52 %) female, giving a male: female ratio of 1.90:1.
For environment and occupation a similar tendency to UC
was observed for CD patients, with the majority living in
urban areas (n = 53; 63.1 %) and engaged in manual labor
(n = 31; 36.90 %). However mean age was younger for CD
(CD: 44.84 years vs. UC: 49.06). Most frequent site of in-
flammation was colon (n = 39; 46.43 %), followed by ileum
(n = 25; 29.76 %) and upper gastrointestinal (n = 13;
Table 1 Proportion of hospitalized patients with IBD of all
gastrointestinal patients in Ningxia hospital from 2002–2014
Year GI Patients (n) IBD (n/%) UC (n/%) CD (n/%)
2002 766 15 (1.96) 15 (1.96) 0
2003 736 16 (2.17) 15 (2.04) 1 (0.13)
2004 900 45 (5.00) 40 (4.44) 5 (0.56)
2005 927 28 (3.02) 21 (2.27) 7 (0.76)
2006 934 32 (3.43) 29 (3.10) 3 (0.33)
2007 872 45 (5.16) 38 (4.36) 7 (0.80)
2008 1246 44 (3.53) 41 (3.29) 3 (0.24)
2009 1334 40 (3.00) 36 (2.70) 4 (0.30)
2010 1629 45 (2.76) 38 (2.33) 7 (0.43)
2011 1642 54 (3.29) 45 (2.74) 9 (0.55)
2012 1768 51 (2.88) 44 (2.49) 7 (0.39)
2013 1762 76 (4.31) 60 (3.41) 16 (0.90)
2014 1803 73 (4.05) 59 (3.27) 14 (0.78)
Fig. 1 Participant Flow
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15.48 %), and ileocolon the least often seen (n = 7; 8.33 %).
Of the CD patients, 22.62 % had stenosis and 5.95 % had
penetrating disease. According to the CDAI [10], 45
(53.57 %) cases were in remission, 25 (29.76 %) had moder-
ate disease activity and 14 (16.67 %) had severe disease ac-
tivity, and because of their disease condition it was
indistinguishable from UC (Table 3).
Diagnostic methods
A comprehensive diagnostic system, which included
clinical manifestation, endoscopy and pathology, was
most widely used in the diagnosis of UC (n = 356;
73.71 %); however comprehensive assessment was less
commonly carried out for CD (n = 2; 2.38 %), with the
diagnosis made on clinical manifestations combined
with colonoscopy for the majority of CD patients (n =
17; 20.24 %). It was difficult to establish the value of
radiology in UC and CD (Table 4).
Treatment
The treatment of CD in hospital was relatively basic,
with most patients treated with 5-amino salicylic acid





Rural, n (%) 209 (43.27)
Urban, n (%) 274 (56.73)
Occupational physical activity
Mild, n (%) 281 (58.18)
Moderate, n (%) 95 (19.67)
Serve, n (%) 107 (22.15)
Age, years, mean ± SD 49.06 ± 14.92
Age at diagnosis, years, mean ± SD 45.98 ± 15.09
Age at diagnosis according to Montreal
classification, n (%)
<17 years 4 (0.83)
17-40 years 129 (26.71)
>40 years 350 (72.46)
Localization of disease according
to Montreal classification, n (%)
E1 Rectum 90 (18.63)
E2 Left colon 160 (33.13)
E3 Extensive colon 233 (48.24)




Mayo Score, n (%)
≦2 and single event ≦1 Clinical remission 179 (37.06)
3-5 Mild activity 11 (2.28)
6-10 Moderate activity 136 (28.16)
11-12 Severe activity 157 (32.50)





Rural, n (%) 31 (36.90)
Urban, n (%) 53 (63.10)
Occupational physical activity
Mild, n (%) 38 (45.24)
Moderate, n (%) 26 (30.95)
Serve, n (%) 20 (23.81)
Age, years, mean ± SD 44.84 ± 14.67
Age at diagnosis, years, mean ± SD 42.68 ± 17.72
Age at diagnosis according to Montreal
classification, n (%)
A1 ≦16 years 6 (7.15)
A2 17-40 years 29 (34.52)
A3 > 40 years 49 (58.33)
Localization of disease, n (%)
L1 Ileum 25 (29.76)
L2 Colon 39 (46.43)
L3 Ileocolon 7 (8.33)
L4 Upper gastrointestinal 13 (15.48)
Illness behavior, n (%)
B1 Non-narrow non-penetrating 60 (71.43)
B2 Stricture 19 (22.62)
B3 Penetrate 5 (5.95)
CDAI, n (%)
≦4 Remission 45 (53.57)
5-8 Moderate activity 25 (29.76)
≧9 Severe activity 14 (16.67)
Table 4 Diagnostic basis
UC CD
n = 483 n = 84
A + D 19 (3.93) 2 (2.38)
A + B 302 (62.53) 17 (20.24)
A + B + C 24 (4.97) 2 (2.38)
A + B + C + D 11 (3.89) 9 (10.71)
Total 356 (73.71) 30 (35.71)
A: Clinical manifestations, B: Colonoscopy, C: Pathology, D: Radiology
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and systemic steroid; the treatment of ulcerative colitis
was more diverse. Table 5 indicates that more than half
(55.69 %) of UC patients were prescribed 5-amino sali-
cylic acid combined with intravenous steroids to con-
trol symptoms, followed by SASP/5ASA alone (n = 156;
32.30 %). Among three adjuvant therapies topical treat-
ment was most common (n = 254; 52.59 %) followed by
antibiotics (n = 231; 47.83 %). Treatment decisions
depended on disease stage and SASP/5ASA only was
used mostly for inpatients with mild disease severity
(56.49 %) gradually decreasing with disease exacerba-
tion, and only used in 10.07 % of severe cases. Overall,
intravenous steroid treatment was more common than
oral, and with aggravation of disease its use increased
concurrently. Although a similar tendency for immuno-
suppressive therapy was seen, only seven patients re-
ceived it, accounting for only 4.7 % of the 149 severely
affected patients.
In our study, surgery was performed in 10 UC pa-
tients (2.07 %) and 9 CD patients(10.71 %). Of the 10
UC cases, 9 cases were with colonic pseudo-polyps, 1
was with lower gastrointestinal bleeding. Of the 9 CD
patients, 3 cases were with anal fistula, 2 cases were
with intestinal obstruction, 2 cases were with acute ileal
perforation, and 1 case was with rectal fistula bladder,
and 1 was with colonic stenosis.
Discussion
Most recent research has reported an obvious trend of
increasing IBD incidence in developing countries; how-
ever trends in IBD in North West China have not been
subject to investigation and this was the first retrospect-
ive study of IBD epidemiology, diagnosis, and treatment
in NingXia area. Our study revealed an upward trend in
incidence of gastrointestinal patients, with the number of
cases of IBD increasing 2.07-fold from 2002 to 2014. Cases
of UC increased 1.67-fold and CD increased 5.57-fold in
this time period, differs from the reported 2.11-fold UC
and 2.78-fold CD over the study years [11]. This difference
may be due to the smaller population quota in North West
China, limited diagnostic facilities or a relatively slow pace
of life leading to a lower incidence of IBD [12]. In Western
countries incidence of UC is slowing decreasing and stabil-
izing, while CD is increasing [13]. However in our study
both diseases have increasing rates, possibly because the
overall development of IBD in China is lagging behind
Western countries. The future direction, i.e., a continued
increase or stabilization can only be monitored by further
long-term observation.
In our study the male/female ratio was 1.22/1 for UC
and 1.90/1 for CD, with both diseases showing a predom-
inating male pattern, especially CD. This difference is con-
sistent with other Asian countries [14], but is not seen in
Western countries. We also observed that the majority of
patients were from urban areas and took serve occupa-
tional physical activity, suggesting environment might play
a more prominent role in the etiology of IBD than life-
style. The mean age of IBD patients in the past 12 years
has not changed significantly, but CD shows a younger
trend (CD: 44.84 years vs. UC: 49.06 years) and this may
be associated with increased awareness of the disease and
effective diagnosis.
Differing from the 2007 consensus on diagnosis and
treatment of inflammatory bowel disease [15], the 2012
version recommended the Montreal classification which
categorizes the location of disease in UC into three sites
[16]. In our study extensive colon involvement is the most
common presentation (48.24 %), which is inconsistent
with the left colon presentation most commonly reported
in many Western countries [17]. Although the majority of
IBD patients in our study presented with mild to moder-
ate disease activity, patients with severe disease activity
accounted for a considerable proportion (30.85 %). This
may be due to the study population being hospitalized pa-
tients, many of whom may have been admitted due to re-
current disease and worsening symptoms.
Our study concurred with the findings of the APDW
2004 Chinese IBD Working Group, that is, less small bowel
disease than colonic disease in Chinese patients [18]; in
Western countries small bowel disease is more common
than colonic disease [19]. This may reflect a real difference
between China and Western countries; however it may be
Table 5 Treatment and disease severity of 483 patients with ulcerative colitis
Mild Moderate Severe Total
n = 154 n = 180 n = 149 n = 483
Antibiotic 52 (33.77) 85 (47.22) 94 (63.09) 231 (47.83)
Topical treatment 36 (23.38) 111 (61.67) 107 (71.81) 254 (52.59)
Chinese medicine (oral/topical) 16 (10.39) 20 (11.11) 35 (23.49) 71 (14.70)
A 87 (56.49) 54 (30.00) 15 (10.07) 156 (32.30)
A + B 16 (10.39) 21 (11.67) 25 (16.78) 52 (10.77)
A + C 47 (30.52) 105 (58.33) 117 (78.52) 269 (55.69)
A + D 0 2 (1.11) 7 (4.70) 9 (1.86)
A: SASP/5ASA, B: Oral steroid, C: Intravenous steroid, D: Immunosuppressive agent
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related to widely applied colonoscopy, limited application
of capsule endoscopy or small intestinal endoscopy, and a
lower rate of surgical intervention in China. Freeman [20]
reported that disease localized to ileum alone was most
often complicated by stricture formation, whereas ileocolic
disease was usually complicated by a penetrating complica-
tion. Our study made similar findings, with stricture forma-
tion noted in 22.62 % of patients and involvement limited
to the ileum in 29.76 % of patients, while ileocolic disease
comprised 8.33 % and penetrating disease 5.95 %. This may
indicate that Crohn's disease is a dynamic process that
phenotypically evolves and progresses with time. In our
study CD patients had better clinical condition than UC pa-
tients; according to CDAI score 53.57 % of CD patients
were in remission.
Our study revealed that clinical manifestation combined
with colonoscopy is the most common diagnostic method
for both UC and CD; however the 2012 consensus re-
ported colonoscopy and biopsy as the main basis for diag-
noses [9]. In our study only 4.97 % patients had findings
such as crypt abscess, atrophic crypt, Paneth’s cell meta-
plasia and other specific histology, causing us to query the
role of biopsy in IBD diagnosis.
Interestingly, in our study the site of CD was situated
more upper gastrointestinal (15.48 %) than ileocolon
(8.33 %) which is the least often seen. This may be owing
to referring to the 2012 Guidelines, only very few cases
(n = 11,13 %) were definited diagnosed, other 23 % were
clinically diagnosed and 64 % were just suspected, so the
diagnosis rate are too low to get the accurate conclusion.
Moreover, it can also make CD difficult to distinguish
from UC and other intestinal diseases, leading to some pa-
tients being misdiagnosed or diagnosed with suspected
CD. Therefore, the new consensus [9] introduces com-
puted tomography enterography (CTE) and magnetic res-
onance enterography (MRE) and their wide application
may provide a new era for CD diagnosis, however, because
of the cost, technology and other issues, the application
were limited, how to improve the small intestinal diseases
in remote areas has become a major difficulty.
General treatment principles for CD consider the site,
behavior and activity of disease before decisions are
made in consultation with the patient. However, in our
study, the selection of treatment merely depended on
clinician experience, and treatment was very basic,
mainly using 5-aminosalicylic acid alone or combined
with steroids (oral/intravenous). The number of CD
cases was relatively small with most cases in remission.
Fewer cases may cause clinician inattention, with stan-
dardized treatment not implemented. We hope our re-
search creates awareness of the increasing hospitalization
rate of CD and adverse effects for patients, so that clini-
cians can mitigate the development of disease, reducing
the burden on patients.
In general, the most widely used treatment of UC was
SASP/5ASA combined with intravenous steroids, pos-
sibly because our subjects were inpatients with poor dis-
ease states and simultaneous intravenous administration
is a convenient method of treatment. For mildly affected
patients, 56.49 % were treated with SASP/5ASA, and the
application of steroids gradually increased with the aggra-
vation of disease, consistent with the recommended guide-
lines [9]. Using Mayo score [21] at discharge to assess the
effects of treatment, our data revealed that the majority of
cases were in clinical remission, suggesting effective treat-
ment for most. For cases not in remission at discharge,
28.16 % were classified as moderate and 2.28 % severe,
suggesting poor control for some patients. Undoubtedly,
this is related to extremely limited application of immuno-
suppressive agents, even in patients with severe disease ac-
tivity, with only 4.7 % receiving this treatment option.
Despite improved aware of the serious consequences of
antibiotic abuse and measures to limit their use in recent
years, 47.83 % of patients in our study were treated with
antibiotics. This number grew with exacerbation of dis-
ease, in some cases due to a genuine need due to cyto-
megalovirus (CMV) or clostridium (CDI) infection. In
other cases, poor control by essential drugs may have re-
sulted in the use of experimental antibiotic therapy. It has
been reported that the prevalence of CMV infection in
acute severe colitis is between 21 % and 34 % [22, 23], and
the prevalence of CDI infection increased from 1.8 % in
2004 to 4.6 % in 2005 [24]. Even though there are multiple
diagnostic tests available for detecting infection, there are
problems with these tests which remain controversial.
Diagnosis and treatment standardization of these infec-
tions will possibly mitigate the abuse of antibiotics in IBD.
Chinese medicine played an important role, especially
in patients with moderate-severe activity, this is different
from the western countries. However, its specific role
and efficient components are still unknown and need
further study. Relatively the operation rate is low, and
CD patients were more frequent (10.71 %, UC 2.07 %),
fistula and stenosis were the main reason.
In addition, only 8.86 % UC and 13.09 % CD patients
can get a definite diagnosis in our study, 66.46 % UC
and 22.62 % CD were clinically diagnosed, 26.29 % UC
and 64.29 % CD were just suspicious. Perhaps there are
some indeterminate colitis. However, due to the lack of
understanding of this type, it was classified as UC or
CD based on the physicians’ clinical experience in ac-
tual clinical diagnosis. By reviewing the medical records
of inpatients with IBD over 12 years and the further
learning the guidelines, we hope to increase the aware-
ness of IBD and the understanding of indeterminate
colitis in the future clinical practice.
This was a retrospective analysis, and the lack of follow-
up information meant we were unable to make a
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comprehensive evaluation of treatment effectiveness.
However, it is evident that the monitoring of IBD patients
should be strengthened, with the establishment of a com-
prehensive follow-up system.
Conclusions
An increasing trend of admissions for IBD can be ob-
served in our study; there are some differences in clinical
features and treatment compared with Western coun-
tries, and further research into this is required.
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